Send me real-time posts from this site at my email

Why Athira Pharma Stock Imploded Today

What happened

Athira Pharma's (NASDAQ: ATHA) stock crumbled by more than 69.5% as of 10:04 a.m. ET Wednesday after the company reported that results from a phase 2 clinical trial for its drug treating mild to moderate Alzheimer's disease didn't reach statistical significance. The company said that its medicine, called fosgonimeton, was less effective than expected in the context of the study because it was co-administered with another drug that potentially interfered with it.

So what

The phase 2 failure bodes poorly for Athira's future, as it still has an ongoing phase 3 trial for fosgonimeton in Alzheimer's disease that's due to finish enrollment by the end of the third quarter.

Beyond that, it only has two other clinical-stage programs, so another stumble with fosgonimeton could spell the end of a large portion of its pipeline. But, the phase 2 trial was designed as a proof-of-concept study to learn more about the biological effects of the drug, so the company can still try to frame the results as a success.

Now what

Given that it has more than $263.5 million in cash and trailing-12-month operating expenses of only around $67.3 million, it won't have any trouble continuing its research and development expenditures at their present level for the foreseeable future, so this setback isn't the end of the company.

Management claims that its analysis of a subgroup of patients in the trial who received fosgonimeton but not the potentially interfering drug showed improvements in cognitive functioning on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) diagnostic questionnaire. So, it plans to use that insight to tweak the parameters of one of its other ongoing studies and increase its chance of success.

10 stocks we like better than Athira Pharma, Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Athira Pharma, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of June 2, 2022

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.


Popular posts

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue